Pathologically elevated blood fat levels in obesity: Researchers discover molecular causes
... also promotes fat breakdown in the liver. Cancer patients, too, might benefit from these findings. Many of them suffer from what is called tumor cachexia a life-threatening loss of weight that is associated with the development of fatty liver. "We have found first evidence suggesting that LSR is ...New Blood Test Better Identifies Heart Failure Patients in ER
... and critical care cardiologists," said Stefan D. Anker, M.D., Ph.D., co-principal investigator of the study and professor of cardiology and cachexia (malnutrition and wasting in the context of disease) research at Campus Virchow-Klinkum (Virchow Hospital) of the Charite Medical School, Berlin, ...A common denominator of inflammations and fatty liver
... mass are reduced, free fatty acids accumulate in the liver, and this eventually leads to fatty liver in affected patients. What is called tumor cachexia appears to be caused by signals emitted by the tumor itself. Despite vigorous searching, scientists have not yet been able to identify these ...Explaining chemotherapy-associated nausea
... hopefully more effective drug treatment regimens, said lead author Bart De Jonghe, PhD, a Monell physiologist. Anorexia (loss of appetite) and cachexia (a syndrome of physical wasting and weight loss) often accompany chemotherapy-induced symptoms of nausea and vomiting. These side effects can ...Loss Of Dystrophin: Common Thread In Cancer And MS Muscle Wasting
... dystrophin levels were reduced in the muscles of mice with cancer cachexia, and that two DGC proteins were altered. The researchers then showed that cachexia is accelerated in mice that lack dystrophin and develop cancer. Furthermore, they showed that they could prevent cancer wasting in the mice by ...Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
... is scheduled for 4:25 p.m. About Cancer cachexia and VT-122 Cancer cachexia results in severe wasting of muscle and ... distressing conditions of advanced cancer. Severe cachexia is associated with extreme weakness, intolerance ...GTx Announces Presentation of Ostarine and Acapodene Data at 2007 ASCO Annual Meeting
... a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic ...Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
... is scheduled for 4:25 p.m. About Cancer cachexia and VT-122 Cancer cachexia results in severe wasting of muscle and ... distressing conditions of advanced cancer. Severe cachexia is associated with extreme weakness, intolerance ...Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
... things, some of the most problematic symptoms associated with clinical cachexia or the so called wasting syndrome. In addition, AVR118 and AVR123 have ... in animal models. Various degenerative conditions associated with cachexia such as cancer, HIV-AIDS and chronic inflammation are potential disease ...Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
... with an initial focus on cachexia. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of ...Vicus Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
... responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of ...Vicus Therapeutics' Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
... responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of ...Introducing Strativa Pharmaceuticals
... launched its first product, Megace(R) ES, in July 2005. Megace ES (megestrol acetate) oral suspension is indicated for anorexia (loss of appetite), cachexia (severe malnutrition), and/or an unexplained, significant weight loss in patients with acquired immunodeficiency syndrome (AIDS). Megace ES generated ...